C. Becker

发表

Macro/nao-structured silicon as solid support for antibody arrays

H. Lilja, J. Malm, T. Laurell, 2005 .

Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific Antigen

O. Nilsson, H. Lilja, F. Kreutz, 1999, Tumor Biology.

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

G. Berglund, J. Hugosson, H. Lilja, 2006, Clinical chemistry.

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

J. Adolfsson, H. Lilja, U. Norming, 1999, Urology.

Association Between Endothelial Cell Stabilizing Medication and Small Vessel Disease Stroke: A Case-Control Study

T. Quinn, Anna C. Williams, C. Becker, 2019, Front. Neurol..

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.

J. Hugosson, H. Lilja, G. Aus, 2004, European urology.

Increased plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide in patients with mild primary hyperparathyroidism

J. Svensson, L. Bondeson, A. Bondeson, 2006, Clinical endocrinology.

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses

A. Vickers, H. Scher, H. Lilja, 2012, Clinical chemistry and laboratory medicine.

Individual prostate-specific antigen (PSA) forms as prostate tumor markers.

H. Lilja, C. Becker, Hans Lilja, 1997, Clinica chimica acta; international journal of clinical chemistry.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

P. Scardino, J. Eastham, G. Berglund, 2008, BMC medicine.

Variation in percentage‐free prostate‐specific antigen (PSA) with prostate volume, age and total PSA level

H. Lilja, U. Norming, O. Gustafsson, 2001, BJU international.

Would prostate cancer detected by screening withprostate‐specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population‐based studies in Sweden

J. Hugosson, H. Lilja, G. Aus, 2000, BJU international.

Free‐to‐total prostate‐specific antigen ratio as a predictor of non‐organ‐confined prostate cancer (stage pT3)

J. Hugosson, H. Lilja, G. Aus, 2003, Scandinavian journal of urology and nephrology.

Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk

J. Malm, J. Manjer, L. Bondeson, 2012, International journal of cancer.

Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies.

P. Porela, L. Voipio‐Pulkki, K. Pulkki, 2005, Clinical chemistry.

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

J. Hugosson, H. Lilja, T. Piironen, 2003, The Journal of urology.

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.

H. Lilja, T. Piironen, K. Pettersson, 2000, Clinical chemistry.

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Andrew J Vickers, Thomas Björk, Hans Lilja, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study.

J. Svensson, L. Bondeson, A. Bondeson, 2004, Surgery.

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.

Hartwig Huland, Markus Graefen, Andreas Erbersdobler, 2003, The Journal of urology.

The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease

E. Diamandis, H. Lilja, J. Noldus, 2001, Critical reviews in clinical laboratory sciences.

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

A. Haese*, H. Lilja, M. Graefen, 2000, The Journal of urology.

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

Hartwig Huland, Andrew J Vickers, Kim Pettersson, 2006, International journal of cancer.

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

M. Kattan, P. Scardino, A. Haese*, 2003, The Prostate.

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate‐specific antigen

P. Scardino, A. Vickers, J. Hugosson, 2010, Cancer.

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

Andrew J Vickers, Kim Pettersson, Angel M Cronin, 2008, BMC medicine.

Interference Testing of the Creatinine Sensor in the Abl837 Flex Analyzer

K. Strandberg, C. Becker, Anne Skurup, 2007 .

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml

A. Haese*, H. Lilja, M. Graefen, 2001, The Prostate.

A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits.

Å. Lernmark, C. Törn, S. Ivarsson, 2008, Clinical laboratory.

Assessment of intra‐individual variation in prostate‐specific antigen levels in a biennial randomized prostate cancer screening program in Sweden

J. Hugosson, H. Lilja, A. Christensson, 2005, The Prostate.

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

P. Scardino, J. Eastham, G. Berglund, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.

J. Hugosson, H. Lilja, T. Piironen, 2000, Urology.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

J. Oesterling, H. Lilja, T. Piironen, 2000, The Journal of urology.

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.

H. Lilja, A. Christensson, T. Björk, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Comparison of Measurements of Autoantibodies to Glutamic Acid Decarboxylase and Islet Antigen-2 in Whole Blood Eluates from Dried Blood Spots Using the RSR-Enzyme Linked Immunosorbent Assay Kits and In-House Radioimmunoassays

C. Törn, Ida Hansson, A. Nilsson, 2010, Experimental diabetes research.

C-peptide in dried blood spots

C. Törn, M. Fex, C. Becker, 2010, Scandinavian journal of clinical and laboratory investigation.

Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling

M. Vihinen, H. Lilja, B. Villoutreix, 1998, Protein science : a publication of the Protein Society.

Identification of plasma protein profiles associated with risk groups of prostate cancer patients

H. Lilja, C. Rose, A. Bjartell, 2014, Proteomics. Clinical applications.

Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues

H. Lilja, A. Christensson, A. Bjartell, 2003, The Prostate.

Increase of bioavailable testosterone is associated with gain in bone mineral density after cure of primary hyperparathyroidism in postmenopausal women

J. Svensson, L. Bondeson, A. Bondeson, 2006, Clinical endocrinology.

Characterization of Epitope Structure for 53 Monoclonal Antibodies against Prostate-Specific Antigen

H. Lilja, C. Becker, I. Wigheden, 1999, Tumor Biology.

Macro/nano-structured silicon as solid support for antibody arrays: Surface design, reproducibility, and assay characteristics enabling discovery of kallikrein gene products for prostate disease diagnostics

H. Lilja, J. Malm, T. Laurell, 2005 .

Integrated selective enrichment target – a microtechnology platform for matrix‐assisted laser desorption/ionization‐mass spectrometry applied on protein biomarkers in prostate diseases

H. Lilja, J. Malm, S. Ekström, 2004, Electrophoresis.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

P. Scardino, J. Eastham, G. Berglund, 2008, BMC medicine.

Comparison of Measurements of Autoantibodies to Glutamic Acid Decarboxylase and Islet Antigen-2 in Whole Blood Eluates from Dried Blood Spots Using the RSR-Enzyme Linked Immunosorbent Assay Kits and In-House Radioimmunoassays

C. Törn, Ida Hansson, A. Nilsson, 2010, Experimental diabetes research.